Medicover AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0009778848
SEK
231.00
-2 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medicover AB stock-summary
stock-summary
Medicover AB
Pharmaceuticals & Biotechnology
Medicover AB is a Sweden-based healthcare and diagnostic services provider. It offers a broad range of healthcare services and hub-and-spoke diagnostic laboratory network, supported by proprietary software and information systems infrastructure. The Company offers its services through two divisions: Healthcare Services and Diagnostic Services. The Healthcare Services division offers services ranging from primary care to specialist outpatient and inpatient care. The care is delivered mainly through Medicover’s own network of clinics and medical facilities. The Diagnostic Services division offers a broad range of diagnostic laboratory testing for humans and some veterinary services across all main clinical pathology specialties. The Company focuses primarily on such markets, as Poland, Germany, Romania, Ukraine.
Company Coordinates stock-summary
Company Details
Riddargatan 12 3Tr , STOCKHOLM None : 114 35
stock-summary
Tel: 46 8 4001760046 8 40017606
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Fredrik Stenmo
Chairman of the Board
Mr. Fredrik Ragmark
Chief Executive Officer, Director
Mr. Peder af Jochnick
Director
Mr. Robert af Jochnick
Director
Mr. Arno Bohn
Independent Director
Mrs. Sonali Chandmal
Independent Director
Mr. C. Michael Flemming
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6,539 Million
(Quarterly Results - Jun 2025)
Net Profit:
197 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 17,808 Million (Small Cap)

stock-summary
P/E

59.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.06%

stock-summary
Debt Equity

1.68

stock-summary
Return on Equity

12.96%

stock-summary
Price to Book

3.17